Option chain shows key data for Utah Medical Products's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Utah Medical Products.

Utah Medical Products (NASDAQ:UTMD) Stock, Option Chain

Utah Medical Products

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

ADIA

AEGN

AEIS

AFIN

AGRX

ALIAF

ALLE

ALPP

AMCT

AMGN

AOSL

APTV

AQUA

ARES

ARNC

AROW

ARWR

ASFI

ASPU

ATEC

ATKR

ATUS

AVGOP

BASI

BEVVF

BF-B

BIOAQ

CABA

CADNF

CARO

CASY

CBKW

CBSH

CCBG

CHCT

CHTR

CMPR

CNMD

CODI

CRWS

CSVI

CUBI

CUPUF

DCPH

DGII

DIOD

DOCU

DOOR

EBSB

EGRX

EHMEF

ESGRO

ESGRP

FAST

FBHS

FDEF

FISI

Stocks That Hit 52-Week Highs On Monday

After-Hours Center

MLHR

MTEM

TLRY

TORC

UTMD

XBIO

9 Stocks Moving In Wednesday&#39;s After-Hours Session

Biotech

Health Care

Pre-Market Outlook

General

ACHV

APTO

ATOS

BHVN

BLFS

CATB

CYTX

EARS

EXAS

GALT

INSP

OBSV

PTCT

SNOA

SRPT

SRTS

SURF

TSRO

VIVO

VSTM

Benzinga&#39;s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Utah Medical Products, Inc. - Common Stock

Utah Medical Products Inc

Utah Medical Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S. in Communications from Santa Clara University and an MBA from the Northwestern University Kellogg School of Management. As she served in her last position as UTMD's manager of Global Direct End User Sales, the Board believes her robust understanding of the functional and strategic challenges that the Company faces will be integral for achieving future revenue growth.
In addition, the Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on January 3, 2025 to shareholders of record at the close of business on December 16, 2024. This is a 1.7% increase over the prior regular quarterly cash dividend.

Dividends

Utah Medical Products Increases Quarterly Dividend From $0.30 To $0.305 Per Share

Utah Medical Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) reported quarterly earnings of $1.02 per share. This is a 5.09 percent decrease over earnings of $1.08 per share from the same period last year. The company reported $10.01 million in sales this quarter. This is a 19.99 percent decrease over sales of $12.51 million the same period last year.

Earnings

Utah Medical Products Q3 EPS $1.025 Down From $1.08 YoY, Sales $10.01M Down From $12.51M YoY

A noteworthy insider acquisition was disclosed on December 26, as Koopman, Principal Financial Officer at Utah Medical Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>), reported the acquisition of stock options for 500 shares.
What Happened: Koopman, Principal Financial Officer at Utah Medical Products, engaged in a derivative transaction according to a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000706698/000173361423000005//Archives/edgar/data/706698/000173361423000005/0001733614-23-000005-index.htm">U.S. Securities and Exchange Commission</a>. This involved the acquisition of stock options for 500 shares of UTMD, providing the right to purchase the company's stock at an exercise price of $77.07 per share.
Utah Medical Products shares are trading, exhibiting down of 0.0% and priced at $85.84 during Wednesday's morning. This values Koopman's 500 shares at $4,385.
<h3>Get to Know Utah Medical Products Better</h3>
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.
<h3>Financial Insights: Utah Medical Products</h3>
Revenue Growth: Utah Medical Products's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -3.47%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 58.85%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.08, Utah Medical Products showcases strong earnings per share.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 18.46, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 6.06 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 8.95, Utah Medical Products presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000706698">Check Out The Full List Of Utah Medical Products's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Smart Decision: Brian Koopman Acquires Utah Medical Products Stock Options

Utah Medical Products Q3 EPS $1.081 Down From $1.178 YoY, Sales $12.51M Down From $12.96M YoY

Utah Medical Products Q1 Revenues Up 1.6% YoY, EPS Up 20.2%

Utah Medical Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) reported quarterly earnings of $1.25 per share. This is a 11.18 percent increase over earnings of $1.13 per share from the same period last year. The company reported $13.57 million in sales this quarter. This is a 5.12 percent increase over sales of $12.91 million the same period last year.

Utah Medical Products Q4 EPS $1.25 Up From $1.13 YoY, Sales $13.57M Up From $12.91M YoY

Utah Medical Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) announces that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($.295) per share of common stock payable on January 4, 2023 to shareholders of record at the close of business on December 16, 2022. This is a&nbsp;1.7%&nbsp;increase over the prior regular quarterly cash dividend.

Utah Medical Products Increases Regular Quarterly Dividend From $0.29 To $0.295

Utah Medical Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) reported quarterly earnings of $1.18 per share. This is a 2.43 percent increase over earnings of $1.15 per share from the same period last year. The company reported $12.96 million in sales this quarter. This is a 3.05 percent increase over sales of $12.57 million the same period last year.

Utah Medical Products Q3 EPS $1.18 Up From $1.15 YoY, Sales $12.96M Up From $12.57M YoY

Utah Medical Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) reported quarterly earnings of $1.12 per share. This is a 7.66 percent increase over earnings of $1.04 per share from the same period last year. The company reported $13.43 million in sales this quarter. This is a 6.54 percent increase over sales of $12.60 million the same period last year.

Utah Medical Products Q2 EPS $1.12 Up From $1.04 YoY, Sales $13.43M Up From $12.60M YoY

Options

UNIT

UPST

UROY

USAU

VAPO

VBNK

VIRT

VRNS

VSAT

VSEC

VSTO

VTEX

VZLA

WLMS

WSBC

WTBA

XBIT

Stocks That Hit 52-Week Lows On Thursday

TDUP

TECH

THRY

TIGO

TNDM

TNGX

TNON

TPHS

Tempest Therapeutics, Inc. - Common Stock

TPST

TRIP

TRMB

TRNO

TROW

TRTX

TRUE

TSLX

TSVT

TTOO

TTSH

TWKS

TWOU

TWST

UBER

VATE

VAXX

VCEL

VCSA

VERI

VERV

VERX

VIAV

VINP

VITL

VLNS

VLTA

VMEO

VORB

VRSK

VSCO

VVNT

WAVD

WEJO

WILC

WOLF

WRLD

WTRG

WULF

XPER

XPON

YORW

Stocks That Hit 52-Week Lows On Tuesday

Utah Medical Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) reported quarterly earnings of $0.96 per share. This is a 16.57 percent increase over earnings of $0.83 per share from the same period last year. The company reported $12.32 million in sales this quarter. This is a 12.40 percent increase over sales of $10.96 million the same period last year.

Utah Medical Products Q1 EPS $0.96 Up From $0.83 YoY, Sales $12.32M Up From $10.96M YoY

Utah Medical Products Q4 Revenues Grew 8% YoY

Utah Medical Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTMD#NASDAQ">UTMD</a>) announces that its Board of Directors approved a special cash dividend of two dollars&nbsp;($2.00)&nbsp;per share of common stock payable on December 29, 2021 to stockholders of record at the close of business on December 15, 2021. This dividend replaces the normal quarterly dividend, and will be paid in December rather than in early 2022.
A key long term UTMD business objective has been to maximize returns for its stockholders. In recent years, the annual dividend distributed has been about&nbsp;$4 million&nbsp;per year. In 2019 and in 2021 to date (excluding the 2020 pandemic year in which net income was temporarily depressed), dividends represented about&nbsp;28%&nbsp;of UTMD&#39;s net income (after a provision for corporate income taxes).
Chairman Kevin Cornwell states, &quot;I would like to help explain the rationale for this&nbsp;$7.3 million&nbsp;special dividend:
A) UTMD generally endeavors to utilize cash not needed to support normal operations in one or a combination of the following:
1) to continue to invest at an opportune time in ways that will enhance future profitability;
2) to make additional investments in new technology and/or processes; and/or
3) to acquire a product line or another company that will augment revenue and EPS growth, better utilizing UTMD&#39;s existing infrastructure.
According to its SEC filings, when UTMD has grown cash beyond these three strategic uses, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.
At September 30, 2021 UTMD&#39;s cash and investment balances at&nbsp;$64.3 million&nbsp;were&nbsp;$12.7 million&nbsp;higher than at December 31, 2020 despite having previously paid&nbsp;$3.1 million&nbsp;in dividends during the first nine months of 2021. During 2020, in addition to paying&nbsp;$4.1 million&nbsp;in dividends to stockholders, UTMD used&nbsp;$7.0 million&nbsp;of cash to repurchase its shares in the open market, thus improving remaining stockholders&#39; value. Because the Company has not been able to repurchase shares in 2021, the special dividend can be viewed as the Board of Directors returning cash in the form of a dividend in lieu of repurchasing shares.
B) For investors subject to income taxes on dividends, a larger and earlier dividend payment should be of benefit given anticipated changes in 2022 U.S. income tax provisions.
C) UTMD will retain its ability to allocate cash according to the three strategic uses above after distribution of this special dividend, because management estimates that the Company&#39;s cash balance at December 31, 2021 will remain close to what was at September 30, 2021 due to continued excellent operating performance.&quot;
Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected or expected.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD&#39;s website at<a href="https://pr.report/5R9x0Sao">www.utahmed.com</a>.

Utah Medical Products Announces Special Dividend Of $2/Share

Utah Medical Products (NASDAQ:<a class="ticker" href="/stock/UTMD#NASDAQ">UTMD</a>) reported quarterly earnings of $0.83 per share. This is a 1.55 percent decrease over earnings of $0.84 per share from the same period last year.

Utah Medical Products Q1 EPS $0.83 Down From $0.84 YoY

Comments

Utah Medical Products

Utah Medical Products (UTMD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga